Imaging and Fluid Biomarkers of Disability Progression During 2 Years of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People with Multiple Sclerosis (MS) in CHIMES (S3.004)
To analyze disease activity via MRI and blood biomarkers at Week 96 of the CHIMES ocrelizumab trial (NCT04377555).
Authors
- Jinglan Pei
- David Clayton (ORCID: https://orcid.org/0000-0002-3850-8200)
- Ibraheem Abioye
- Evanthia Bernitsas (ORCID: https://orcid.org/0000-0001-9382-1008)
- Gregory F. Wu (ORCID: https://orcid.org/0000-0003-3588-0637)
- Lilyana Amezcua (ORCID: https://orcid.org/0000-0003-1542-7819)
- Timothy Vartanian (ORCID: https://orcid.org/0000-0001-9471-1855)
- Christopher Harp (ORCID: https://orcid.org/0000-0001-7000-8743)
- Anthony T. Reder (ORCID: https://orcid.org/0000-0002-6423-1495)
- Mitzi Williams (ORCID: https://orcid.org/0000-0001-6979-1101)
- Nancy Monson
Institutions
- University of Southern California (US)
- Wayne State College (US)
- Cornell University (US)
- California Southern University (US)
- University of Chicago (US)
- Southwestern University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210703
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47